The Power of Intelligent ePrescribing
The Power of Intelligent ePrescribing
Formulary & Benefit (F&B), Real Time Prescription Benefits (RTPB), and electronic Prior Authorization (ePA) are all tools to help make prescribing more efficient and cost concious.
By displaying the benefit information at the point of decision, prescribers can make the most informed decisions about their patient's prescription.
These tools help the prrovider optimize prescribing by selecting the lower cost, therapeutically similar medications, with less coverage restrictions.
0%+
Typical Drug Coverage
$16-0M+
Drug Savings per 1M Patients
28-0%
Typical Drug Switch Rate
SmartAlts™ Delivers Intelligent ePrescribing
SmartAlts provide the most intelligent, therapeutically similar, lowest cost drug alternatives so prescribers can bypass the cumbersome processes for researching alternatives, rewriting prescriptions, and reducing pharmacy callbacks.
SmartAlts are seamlessly displayed in the prescriber's Electronic Health Record/Electronic Medical Record (EHR/EMR) and improve what is shown by including other useful benefit information like formulary status, copay, and coverage restrictions. With SmartAlts, prescribers can select the most clinically appropriate low lower cost products the first time, increasing patient adherence, improving outcomes, and reducing costs.
As a result, the patients typically pay less for their medication, while your health care organization can achieve substantial savings depending upon the patient population you are serving.
How Do They Work?
Intelligent ePrescribing is powered by a proprietary solution which is rooted in the most current research. See an example of the SmartAlts solution for an HMG-CoA Statins therapeutic category, based on the Low-Density Lipoprotein (LDL) drugs.
Learn More
How are Therapeutically Similar SmartAlts™ Determined
The therapeutically similar alternatives are determined for a particular drug or product regardless of pharmacy benefit plan based on a broad array of published information as reviewed and approved by the Pharmacy and Therapeutics (P&T) Committee. Also, the clinical team reviews additions, deletions and modifications every week.
A review of FDA approved indication(s) and information supplied by the FDA is assessed. Then, peer reviewed scientific literature such as the following is referenced:
SmartAlts™ can substancially reduce drug costs as well as maximise patient affordability and adherence
Therapeutically SImilar
420+ Therapeutic Classes
Rich Formulary & Coverage
Prior Authorization Visibility